Table 1.
Baseline characteristics of patients and PJI according to eligibility for phage therapy
| Group 1 Ineligible | Group 2 Eligible | p-value | |
|---|---|---|---|
| Total (N) | 36 | 42 | |
| Age (mean in years) | 60.2 ± 18.2 | 71.1 ± 13.7 | 0.005 |
| BMI (mean in kg/m2)* | 27.8 ± 5.9 | 30.3 ± 7.8 | - |
| Female Sex (%)* | 16 (44.4) | 18 (42.6) | 0.93 |
| Albumin level (mean in g/L)* | 35.1 ± 8.6 | 30.6 ± 6.4 | - |
| Allergy (n, %)* | 3 (8.3) | 6 (14.3) | - |
| Diabetic (n, %) | 3 (8.3) | 11 (26.2) | 0.008 |
| GFR < 30 mL/min (n, %)* | 0 (0) | 2 (4.7) | - |
| Hepatocellular insufficiency (n, %)* | 2 (5.6) | 3 (7.1) | - |
| Cardiopathy (n, %)* | 7 (19.4) | 22 (52.3) | - |
| Immunocompromised (n, %)* | 1 (2.8) | 9 (21.4) | - |
| At least one major medical comorbidity (n, %)* | 22 (61.1) | 39 (92.9) | - |
| Late infection (n, %) | 18 (50.0) | 28 (66.6) | 0.2 |
| Chronic infection (n, %) | 10 (27.8) | 22 (52.4) | 0.049 |
| Material withdrawal (n, %) | 21 (58.3) | 21 (50.0) | 0.45 |
| Staphylococcus aureus(n, %) | 20 (55.6) | 19 (45.2) | 0.56 |
| Negative CoagulaseStaphylococcus(n, %) | 10 (27.8) | 6 (14.3) | 0.27 |
| Enterobacteria (n, %) | 2 (5.6) | 7 (16.7) | 0.22 |
| Pseudomonas aeruginosa(n, %) | 1 (2.7) | 3 (7.1) | 0.7 |
| More than one bacteria (n, %)* | 8 (22.2) | 0 (0) | - |
| MRSA (n, %)* | 0 (0) | 6 (14.3) | - |
| ESBL (n, %)* | 0 (0) | 2 (4.8) | - |
| Fluoroquinolone resistance (n, %)* | 3 (8.3) | 6 (14.3) | - |
| Rifampicine resistance (n, %) | 0 (0) | 0 (0) | |
| MDR bacteria (n, %)* | 0 (0) | 8 (19.0) | - |
Plus-minus values are means +/- SD. Abbreviations: BMI: Body Mass Index, GFR: Glomerular Filtration Rate, MRSA: Methicillin Resistant Staphylococcus aureus, ESBL: Extended Spectrum Beta-Lactamases, MDR : Multi-Drug Resistant
* Statistical analysis was not performed on characteristics corresponding to eligibility or exclusion criteria.